{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Reducing Fat &amp; Reducing Mortality &amp; Stroke; Tirzepatide s. Dulaglutide; Finerenone and Hypotension; Low Operator Volume and Worse Outcomes ","description":" In this week\u2019s View, Dr. Eagle\u202fevaluates&amp;nbsp;the impacts&amp;nbsp;that&amp;nbsp;reducing saturated fat&amp;nbsp;have&amp;nbsp;on&amp;nbsp;mortality,&amp;nbsp;nonfatal myocardial infarction&amp;nbsp;(NFMI), and stroke in&amp;nbsp;high-risk individuals.\u202fHe then\u202fexplores\u202fthe\u202fSURPASS-CVOT study&amp;nbsp;which considers&amp;nbsp;if tirzepatide is superior to dulaglutide in&amp;nbsp;patients&amp;nbsp;with type 2&amp;nbsp;diabetes&amp;nbsp;and&amp;nbsp;atherosclerotic cardiovascular disease (ASCVD).&amp;nbsp;Next, he summarizes the FINEARTS-HF study and its investigation of&amp;nbsp;finerenone&amp;nbsp;and hypotension and&amp;nbsp;CV&amp;nbsp;outcomes according to baseline kidney function.&amp;nbsp;\u202fFinally,\u202fDr. Eagle&amp;nbsp;examines how low operator volume&amp;nbsp;is associated&amp;nbsp;with&amp;nbsp;worse&amp;nbsp;transcatheter aortic valve replacement\u202f(TAVR)&amp;nbsp;and&amp;nbsp;mitral transcatheter edge-to-edge repair (MTEER)&amp;nbsp;outcomes.\u202f\u202f\u202f&amp;nbsp;   \u202fSubscribe to Eagle\u2019s Eye View\u202f\u202f&amp;nbsp;  ","author_name":"Eagle's Eye View: Your Weekly CV Update From ACC.org","author_url":"http:\/\/www.acc.org","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/39714370\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/197450825"}